Do Adjunctive Anti-scarring Agents Including Mitomycin-C Improve Glaucoma Tube Shunt Surgery: Systematic Review and Meta-analysis.

Authors

Varen Zhi Zheng Tan, Miao Li Chee, Nicole Xer Min Lau, Jayden Wen Yap, Nicole Shu-Wen Chan, Katherine Wanxian Lun, Yih Chung Tham, Victor Koh Teck Chang

Published in

Ophthalmic epidemiology. Pages 1-11. Nov 11, 2026. Epub Nov 11, 2026.

Abstract

Adjunctive anti-scarring agents (ASAs), including mitomycin C (MMC), 5-Fluorouracil (5FU), corticosteroids and vascular endothelial growth factor antagonists (anti-VEGF), aim to improve glaucoma tube shunt (GTS) surgery by attenuating peri-endplate fibrosis. While used in trabeculectomy, ASAs are less established in GTS surgery, leading to varied practices. This systematic review and meta-analysis evaluated their efficacy and safety.
Prospectively registered in PROSPERO (CRD 4,202,236,526), MEDLINE, EMBASE, and CENTRAL were searched for randomised controlled trials (RCTs) and comparative cohort studies (CCSs) comparing ASA and non-ASA use in GTS surgery. Outcomes included changes in intra-ocular pressure (IOP), anti-glaucoma medications, re-operation, and complication rates between baseline and post-operative months 3, 6, and 12.
28 studies (n = 1621 eyes) were included: 12 RCTs (n = 624 eyes) and 16 CCSs (n = 997 eyes). ASAs included MMC (n = 11/28), corticosteroids (n = 7/28), Anti-VEGF (n = 6/28), and 5FU (n = 2/28). Two studies used dual agents. ASA did not affect post-operative IOP [pooled difference (PD) 1.99 mmHg, 1.06 mmHg, 1.15 mmHg at month 3 (p = 0.059), 6 (p = 0.30), and 12 (p = 0.23), respectively]. ASA and MMC use resulted in fewer anti-glaucoma eyedrops required at month 3, 6, and 12 (PD = 0.56, 0.42, 0.49; p < 0.001, = 0.031, 0.013); (PD = 0.76, 0.73, 0.73; p < 0.001, = 0.001, < 0.013), respectively. Both increased hypotony development risk (OR = 2.06, p = 0.001; OR = 2.27, p = 0.001). All other complication rates were similar (all p > 0.05). The re‑operative rate was lower with MMC (OR = 0.42, p = 0.007).
ASAs, particularly MMC, reduced glaucoma medication burden at 12 months, but increased the risk of post-operative hypotony.

PMID:
43012868
Bibliographic data and abstract were imported from PubMed on 11 Nov 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.